Status:
RECRUITING
Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions:
Pancreatic Cancer Resectable
Pancreatectomy
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this observational study is to determine how often lymph node metastases occur in the splenic hilum and surrounding fat in patients with left-sided pancreatic cancer. The main question th...
Detailed Description
Splenectomy is routinely performed during surgical resection of left-sided pancreatic ductal adenocarcinoma (PDAC) with the primary aim to facilitate adequate lymphadenectomy. However, asplenia is ass...
Eligibility Criteria
Inclusion
- All consecutive adult patients (≥ 18 years) who undergo an open or minimally invasive (i.e., robot-assisted or laparoscopic) left-sided pancreatectomy with concomitant splenectomy for primary resectable, borderline resectable, and locally advanced left-sided PDAC
Exclusion
- Tumor involvement or abutment of the spleen
Key Trial Info
Start Date :
November 28 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2031
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT07157605
Start Date
November 28 2024
End Date
January 1 2031
Last Update
September 5 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
BenQ Hospital
Nanjing, China
2
Konstantopoulio General Hospital
Athens, Greece
3
Padova University Hospital
Padua, Italy
4
Kyushu University Hospital
Fukuoka, Japan